Share Price and Basic Stock Data
Last Updated: January 17, 2026, 8:56 am
| PEG Ratio | 7.42 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Colinz Laboratories Ltd operates within the pharmaceuticals sector, having reported a market capitalization of ₹23.2 Cr and a current share price of ₹50.6. The company’s revenue from operations for the trailing twelve months (TTM) stood at ₹5.88 Cr, marking a decline from ₹7.15 Cr in FY 2023. Quarterly sales figures depicted fluctuations, with the highest quarterly sales of ₹1.92 Cr recorded in September 2022, while the most recent quarter, September 2023, reported sales of ₹1.79 Cr. This trend indicates a potential stagnation in revenue growth, raising questions about market competitiveness. Over the years, the annual sales have shown a decline from ₹7.41 Cr in FY 2014 to ₹6.53 Cr in FY 2025. Despite this downward trajectory, the company has maintained a consistent operational presence, which may reflect a stable client base amidst industry challenges, such as price pressures and regulatory hurdles in the pharmaceutical landscape.
Profitability and Efficiency Metrics
Colinz Laboratories reported a net profit of ₹0.46 Cr for FY 2023, with a net profit margin of 6.39% for the same period. The operating profit margin (OPM) stood at 8.81%, showcasing a reasonable level of operational efficiency considering the competitive nature of the pharmaceutical industry. However, the company’s return on equity (ROE) was recorded at 5.43%, indicating that shareholder returns are relatively low compared to sector averages. The interest coverage ratio (ICR) was a robust 18.70x, showcasing strong earnings relative to interest obligations, hence indicating a low risk of default. The cash conversion cycle (CCC) of 78.81 days suggests that the company effectively manages its inventory and receivables, although there is room for improvement when compared to industry peers. This efficiency could be a key area for Colinz to enhance profitability, especially in a sector where margins are often squeezed.
Balance Sheet Strength and Financial Ratios
The balance sheet of Colinz Laboratories exhibits a conservative financial structure, with total borrowings recorded at ₹0.66 Cr against total assets of ₹12.13 Cr for FY 2025. This results in a debt-to-equity ratio of 0.06, indicating a low reliance on debt financing, which is favorable in times of economic uncertainty. The company’s reserves increased to ₹7.36 Cr, demonstrating a commitment to reinvesting earnings back into the business. The price-to-book value (P/BV) ratio of 1.93x suggests that the stock is trading at a premium relative to its book value, which could be indicative of growth expectations among investors. However, the decline in operating profit from ₹0.63 Cr in FY 2023 to ₹0.49 Cr in FY 2025 raises concerns about future profitability. The current ratio of 4.17x indicates solid liquidity, allowing the company to meet short-term obligations comfortably, which is an essential factor in maintaining operational stability.
Shareholding Pattern and Investor Confidence
Colinz Laboratories has a stable shareholding structure, with promoters holding a significant 66% stake, reflecting management’s strong control and commitment to the company’s long-term vision. The public holds 33.99%, while foreign institutional investors (FIIs) have not reported any holdings. This lack of institutional investment may suggest a cautious outlook from larger investors. The number of shareholders has gradually increased from 2,863 in December 2022 to 3,272 by September 2025, indicating growing retail interest. However, the absence of domestic institutional investment (DIIs) over several quarters raises concerns about institutional confidence in the company’s growth prospects. The consistent promoter shareholding may provide a cushion against volatility, yet the lack of diversified ownership could limit the company’s strategic options and market perception.
Outlook, Risks, and Final Insight
The outlook for Colinz Laboratories presents both opportunities and challenges. The company’s low debt levels and strong interest coverage ratio position it well to weather economic downturns. However, the declining revenue and profitability metrics highlight significant operational challenges that must be addressed to sustain growth. Key risks include the potential for further revenue declines due to competitive pressures and regulatory complexities within the pharmaceutical sector. Additionally, the lack of institutional investment could hinder access to capital for expansion initiatives. To enhance its market position, Colinz may need to innovate its product offerings and improve operational efficiencies. If the company can successfully navigate these risks while leveraging its financial strengths, it could stabilize and potentially grow its market presence in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,884 Cr. | 356 | 479/192 | 80.4 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.23 Cr | 1,115.90 | 52.25 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.92 | 1.68 | 1.72 | 1.90 | 1.79 | 1.71 | 1.63 | 1.75 | 1.86 | 1.47 | 1.45 | 1.57 | 1.39 |
| Expenses | 1.76 | 1.55 | 1.56 | 1.74 | 1.67 | 1.57 | 1.51 | 1.59 | 1.69 | 1.40 | 1.35 | 1.44 | 1.31 |
| Operating Profit | 0.16 | 0.13 | 0.16 | 0.16 | 0.12 | 0.14 | 0.12 | 0.16 | 0.17 | 0.07 | 0.10 | 0.13 | 0.08 |
| OPM % | 8.33% | 7.74% | 9.30% | 8.42% | 6.70% | 8.19% | 7.36% | 9.14% | 9.14% | 4.76% | 6.90% | 8.28% | 5.76% |
| Other Income | 0.05 | 0.04 | 0.04 | 0.04 | 0.08 | 0.05 | 0.11 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.16 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Profit before tax | 0.17 | 0.13 | 0.16 | 0.16 | 0.16 | 0.15 | 0.19 | 0.19 | 0.21 | 0.11 | 0.13 | 0.16 | 0.19 |
| Tax % | 29.41% | 23.08% | 18.75% | 18.75% | 25.00% | 26.67% | 31.58% | 26.32% | 23.81% | 45.45% | -23.08% | 25.00% | 26.32% |
| Net Profit | 0.12 | 0.10 | 0.13 | 0.12 | 0.12 | 0.11 | 0.14 | 0.14 | 0.16 | 0.05 | 0.15 | 0.12 | 0.14 |
| EPS in Rs | 0.26 | 0.22 | 0.28 | 0.26 | 0.26 | 0.24 | 0.31 | 0.31 | 0.35 | 0.11 | 0.33 | 0.26 | 0.31 |
Last Updated: December 27, 2025, 12:07 pm
Below is a detailed analysis of the quarterly data for Colinz Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1.39 Cr.. The value appears to be declining and may need further review. It has decreased from 1.57 Cr. (Jun 2025) to 1.39 Cr., marking a decrease of 0.18 Cr..
- For Expenses, as of Sep 2025, the value is 1.31 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.44 Cr. (Jun 2025) to 1.31 Cr., marking a decrease of 0.13 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Jun 2025) to 0.08 Cr., marking a decrease of 0.05 Cr..
- For OPM %, as of Sep 2025, the value is 5.76%. The value appears to be declining and may need further review. It has decreased from 8.28% (Jun 2025) to 5.76%, marking a decrease of 2.52%.
- For Other Income, as of Sep 2025, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.08 Cr. (Jun 2025) to 0.16 Cr., marking an increase of 0.08 Cr..
- For Interest, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.16 Cr. (Jun 2025) to 0.19 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 26.32%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.32%, marking an increase of 1.32%.
- For Net Profit, as of Sep 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from 0.12 Cr. (Jun 2025) to 0.14 Cr., marking an increase of 0.02 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.31. The value appears strong and on an upward trend. It has increased from 0.26 (Jun 2025) to 0.31, marking an increase of 0.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:56 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 5.88 |
| Expenses | 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.50 |
| Operating Profit | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.38 |
| OPM % | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 6.46% |
| Other Income | 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.40 |
| Interest | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.14 |
| Profit before tax | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.59 |
| Tax % | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | |
| Net Profit | 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.46 |
| EPS in Rs | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.01 | 1.07 | 1.09 | 1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 42.86% | -10.00% | 55.56% | 64.29% | -47.83% | 8.33% | 61.54% | 61.90% | 35.29% | 6.52% | 2.04% |
| Change in YoY Net Profit Growth (%) | 0.00% | -52.86% | 65.56% | 8.73% | -112.11% | 56.16% | 53.21% | 0.37% | -26.61% | -28.77% | -4.48% |
Colinz Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 31% |
| 3 Years: | 14% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 40% |
| 3 Years: | 3% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 10, 2025, 4:05 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.36 |
| Borrowings | 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.66 |
| Other Liabilities | 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 1.59 |
| Total Liabilities | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
| Fixed Assets | 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.62 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.21 |
| Other Assets | 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 9.30 |
| Total Assets | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
Below is a detailed analysis of the balance sheet data for Colinz Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.52 Cr..
- For Reserves, as of Sep 2025, the value is 7.36 Cr.. The value appears strong and on an upward trend. It has increased from 6.96 Cr. (Mar 2025) to 7.36 Cr., marking an increase of 0.40 Cr..
- For Borrowings, as of Sep 2025, the value is 0.66 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.64 Cr. (Mar 2025) to 0.66 Cr., marking an increase of 0.02 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.59 Cr.. The value appears to be improving (decreasing). It has decreased from 1.70 Cr. (Mar 2025) to 1.59 Cr., marking a decrease of 0.11 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.82 Cr. (Mar 2025) to 12.13 Cr., marking an increase of 0.31 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1.62 Cr.. The value appears to be declining and may need further review. It has decreased from 1.70 Cr. (Mar 2025) to 1.62 Cr., marking a decrease of 0.08 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.21 Cr.. The value appears strong and on an upward trend. It has increased from 1.04 Cr. (Mar 2025) to 1.21 Cr., marking an increase of 0.17 Cr..
- For Other Assets, as of Sep 2025, the value is 9.30 Cr.. The value appears strong and on an upward trend. It has increased from 9.08 Cr. (Mar 2025) to 9.30 Cr., marking an increase of 0.22 Cr..
- For Total Assets, as of Sep 2025, the value is 12.13 Cr.. The value appears strong and on an upward trend. It has increased from 11.82 Cr. (Mar 2025) to 12.13 Cr., marking an increase of 0.31 Cr..
Notably, the Reserves (7.36 Cr.) exceed the Borrowings (0.66 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.54 | -2.07 | -1.35 | -0.35 | -0.07 | -0.33 | -0.07 | -0.65 | 0.11 | 0.36 | -0.03 | -0.15 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 |
| Inventory Days | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 |
| Days Payable | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 |
| Cash Conversion Cycle | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 |
| Working Capital Days | 89.65 | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 72.66 |
| ROCE % | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Diluted EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Cash EPS (Rs.) | 2.49 | 2.45 | 2.33 | 1.52 | 0.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Revenue From Operations / Share (Rs.) | 25.91 | 27.91 | 28.40 | 19.67 | 17.37 |
| PBDIT / Share (Rs.) | 3.15 | 3.25 | 3.10 | 2.13 | 0.93 |
| PBIT / Share (Rs.) | 2.63 | 2.73 | 2.59 | 1.57 | 0.93 |
| PBT / Share (Rs.) | 2.46 | 2.58 | 2.38 | 1.35 | 0.69 |
| Net Profit / Share (Rs.) | 1.97 | 1.93 | 1.81 | 0.95 | 0.58 |
| PBDIT Margin (%) | 12.14 | 11.63 | 10.91 | 10.85 | 5.38 |
| PBIT Margin (%) | 10.13 | 9.78 | 9.11 | 7.96 | 5.38 |
| PBT Margin (%) | 9.48 | 9.25 | 8.38 | 6.88 | 3.98 |
| Net Profit Margin (%) | 7.60 | 6.92 | 6.39 | 4.86 | 3.37 |
| Return on Networth / Equity (%) | 5.24 | 5.43 | 5.61 | 4.41 | 2.84 |
| Return on Capital Employeed (%) | 6.85 | 7.49 | 7.81 | 6.99 | 4.41 |
| Return On Assets (%) | 4.20 | 4.28 | 4.47 | 3.41 | 2.05 |
| Total Debt / Equity (X) | 0.06 | 0.06 | 0.03 | 0.06 | 0.13 |
| Asset Turnover Ratio (%) | 0.56 | 0.65 | 0.70 | 0.69 | 0.65 |
| Current Ratio (X) | 4.17 | 4.00 | 4.15 | 3.72 | 2.82 |
| Quick Ratio (X) | 3.81 | 3.62 | 3.66 | 3.26 | 2.34 |
| Inventory Turnover Ratio (X) | 8.02 | 0.56 | 0.66 | 0.55 | 0.37 |
| Interest Coverage Ratio (X) | 18.70 | 21.98 | 14.93 | 10.03 | 3.83 |
| Interest Coverage Ratio (Post Tax) (X) | 12.71 | 14.08 | 9.75 | 5.49 | 3.40 |
| Enterprise Value (Cr.) | 13.34 | 3.03 | 3.36 | 3.63 | -0.99 |
| EV / Net Operating Revenue (X) | 2.04 | 0.43 | 0.46 | 0.52 | -0.16 |
| EV / EBITDA (X) | 16.82 | 3.70 | 4.30 | 4.79 | -3.00 |
| MarketCap / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| Price / BV (X) | 1.93 | 1.06 | 1.08 | 1.09 | 0.36 |
| Price / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| EarningsYield | 0.02 | 0.05 | 0.05 | 0.04 | 0.07 |
After reviewing the key financial ratios for Colinz Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.45 (Mar 24) to 2.49, marking an increase of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.91. It has decreased from 27.91 (Mar 24) to 25.91, marking a decrease of 2.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.15. This value is within the healthy range. It has decreased from 3.25 (Mar 24) to 3.15, marking a decrease of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.63. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.63, marking a decrease of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 2.58 (Mar 24) to 2.46, marking a decrease of 0.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.14. This value is within the healthy range. It has increased from 11.63 (Mar 24) to 12.14, marking an increase of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 9.78 (Mar 24) to 10.13, marking an increase of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.25 (Mar 24) to 9.48, marking an increase of 0.23.
- For Net Profit Margin (%), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 7.60, marking an increase of 0.68.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 5.43 (Mar 24) to 5.24, marking a decrease of 0.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.85. This value is below the healthy minimum of 10. It has decreased from 7.49 (Mar 24) to 6.85, marking a decrease of 0.64.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has decreased from 4.28 (Mar 24) to 4.20, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.65 (Mar 24) to 0.56, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 4.17. This value exceeds the healthy maximum of 3. It has increased from 4.00 (Mar 24) to 4.17, marking an increase of 0.17.
- For Quick Ratio (X), as of Mar 25, the value is 3.81. This value exceeds the healthy maximum of 2. It has increased from 3.62 (Mar 24) to 3.81, marking an increase of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 8. It has increased from 0.56 (Mar 24) to 8.02, marking an increase of 7.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.70. This value is within the healthy range. It has decreased from 21.98 (Mar 24) to 18.70, marking a decrease of 3.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.71. This value is within the healthy range. It has decreased from 14.08 (Mar 24) to 12.71, marking a decrease of 1.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.34. It has increased from 3.03 (Mar 24) to 13.34, marking an increase of 10.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.04. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 2.04, marking an increase of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 16.82. This value exceeds the healthy maximum of 15. It has increased from 3.70 (Mar 24) to 16.82, marking an increase of 13.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For Price / BV (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.93, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Colinz Laboratories Ltd:
- Net Profit Margin: 7.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.85% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.71
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.6 (Industry average Stock P/E: 52.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-101, Pratik Ind.Estate, Mulund-Goregaon Link Road, Mumbai Maharashtra 400078 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. N K Menon | Whole Time Director |
| Mr. A Krishna Kumar | Independent Director |
| Dr. Mani L S | Non Executive Director |
| Mr. Bhavik Ashokkumar Shah | Independent Director |
| Mr. Baptist Bernard Dias | Independent Director |
FAQ
What is the intrinsic value of Colinz Laboratories Ltd?
Colinz Laboratories Ltd's intrinsic value (as of 18 January 2026) is ₹48.48 which is 1.21% higher the current market price of ₹47.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹21.9 Cr. market cap, FY2025-2026 high/low of ₹88.7/36.1, reserves of ₹7.36 Cr, and liabilities of ₹12.13 Cr.
What is the Market Cap of Colinz Laboratories Ltd?
The Market Cap of Colinz Laboratories Ltd is 21.9 Cr..
What is the current Stock Price of Colinz Laboratories Ltd as on 18 January 2026?
The current stock price of Colinz Laboratories Ltd as on 18 January 2026 is ₹47.9.
What is the High / Low of Colinz Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Colinz Laboratories Ltd stocks is ₹88.7/36.1.
What is the Stock P/E of Colinz Laboratories Ltd?
The Stock P/E of Colinz Laboratories Ltd is 47.6.
What is the Book Value of Colinz Laboratories Ltd?
The Book Value of Colinz Laboratories Ltd is 21.6.
What is the Dividend Yield of Colinz Laboratories Ltd?
The Dividend Yield of Colinz Laboratories Ltd is 0.00 %.
What is the ROCE of Colinz Laboratories Ltd?
The ROCE of Colinz Laboratories Ltd is 6.72 %.
What is the ROE of Colinz Laboratories Ltd?
The ROE of Colinz Laboratories Ltd is 5.43 %.
What is the Face Value of Colinz Laboratories Ltd?
The Face Value of Colinz Laboratories Ltd is 10.0.